Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof

A vaccine adjuvant, liposome technology, applied in the directions of medical preparations containing active ingredients, liposome delivery, antibody medical ingredients, etc., can solve problems such as low efficacy, reduced incidence of herpes zoster, and no treatment methods

Pending Publication Date: 2020-04-10
株式会社车疫苗研究所
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since there is no basic cure, it is necessary to develop a vaccine to prevent it
[0006] Although the efficacy of a commercially available shingles vaccine has been demonstrated in clinical trials, the incidence of shingles was reduced by only 50% by administering the vaccine, suggesting little efficacy
In addition, since commercially available shingles vaccines are live attenuated vaccines, they have limitations when administered to immunosuppressed patients with a high incidence of shingles, pregnant women, and persons who may become pregnant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof
  • Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof
  • Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0095] Hereinafter, the present invention will be described in detail by the following examples.

[0096] However, the following examples are only for illustrating the present invention, and the content of the present invention is not limited thereto.

Embodiment 1

[0097] Example 1 Preparation of recombinant varicella-zoster virus gE antigen

[0098] Construction of plasmid

[0099] First, the gene (SEQ.ID.NO: 1) was synthesized to include a restriction enzyme recognition sequence (Nhe I site at 5' and Xho I site at 3') in the outer region of the gE (glycoprotein E) gene expression region of VZV. dots) and kozak sequences. At this point, a codon-optimized sequence for CHO cells, present with the C-terminal anchor domain removed from ORF68 (glycoprotein E) of the complete human herpesvirus type 3 (HHV-3) genome, was used as a template . The 1.6 kb gE gene of VZV represented by SEQ.ID.No: 1 was digested with Nhe I and Xho I restriction enzymes, and subcloned into pPGXII vector. As a result, pPGXII-VZV gE, the VZV gE expression plasmid ( figure 1 ).

[0100] Selection of cell lines

[0101] The DNA of the pPGXII-VZV gE plasmid prepared in Example was linearized with Ahd I restriction enzyme, and by electroporation, it was transfec...

Embodiment 2

[0107] Embodiment 2 Comparison of the immunogenicity of the recombinant vaccine according to the dosage of lipopeptide and Poly(I:C)

[0108] Preparation and administration of test vaccine

[0109] First, to prepare DC-Chol:DOPE liposomes, DC-Chol and DOPE were dissolved in chloroform respectively, and then the organic solvent was vaporized with nitrogen gas while rotating the glass container, so that the ratio of DC-Chol and DOPE was 3:7. The mixed solution is evenly distributed on the bottom wall of the container. At this time, a thin film was formed on the bottom wall. The organic solvent remaining in the formed film was removed by storing in a vacuum desiccator for 1 hour. Distilled water was added to the completely dried lipid film and then fully hydrated using an ultrasonic bath for 10 min. In preparing multilamellar vesicle (MLV) suspensions, a 2X buffer solution (pH 7.0) containing 300 mM NaCl in 20 mM sodium phosphate was added in the same amount as distilled wate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a recombinant herpes zoster vaccine comprising liposome and lipopeptide and a method for preparing the same. More particularly, a vaccine composition according to thepresent invention, prepared using Lipo-Pam, which is a composite adjuvant comprising a liposome and various kinds of lipopeptides, and a varicella-zoster virus gE antigen, a Japanese encephalitis virus gE antigen, or a seasonal inactivated influenza virus antigen, highly induces a cell-mediated immune response as well as a humoral immune response so that the composition of the present invention can be commercially useful.

Description

technical field [0001] The present invention relates to a vaccine adjuvant containing a liposome inserted with a lipopeptide as an active ingredient and its use. Background technique [0002] Chickenpox or herpes zoster (Herpes Zoster) is caused by VZV (Varicella-Zoster Virus, varicella-zoster virus), and is a disease that occurs on the skin in the sensory nerves distributed to a single spinal cord or cranial nerve. In the early stage of VZV infection, the virus proliferates in the epidermis and dermis of the skin, then penetrates into the surrounding nerve cells and remains latent. During the multiplication process preceding the incubation period, varicella develops and a rash appears, and then the virus remains dormant in the ganglion. When the body's resistance declines, VZV reactivates and manifests as shingles. VZV reactivation and the development of herpes zoster are associated with a decrease in T-cell-centric cellular immune responses, especially in the elderly and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/25A61K39/12A61K39/00
CPCA61K39/12A61P31/20C12N2710/16734A61K2039/55555A61K2039/55561A61K2039/575A61P31/14C12N2770/24134C12N2760/16134C12N2760/16234A61P31/16Y02A50/30A61K39/39A61P31/12A61P35/00A61K2039/55516A61K2039/55577A61K2039/57A61P31/22A61K9/127A61K39/145A61K39/25
Inventor 廉晶善安秉喆赵显镇白承希郑银贞郑水镜
Owner 株式会社车疫苗研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com